Gilead's Truvada Approved in China for Preventative HIV Use
August 11 2020 - 8:58AM
Dow Jones News
By Matt Grossman
Gilead Sciences Inc.'s Truvada drug has been approved by the
China National Medical Products Administration for pre-exposure
prophylaxis against sexually acquired HIV-1, Gilead said
Tuesday.
Truvada is the first medication approved for HIV prevention in
China, Gilead said. It had already been approved for that use in
the United States. In China, Truvada was previously approved as a
treatment for HIV-1 infection in combination with other
antriretroviral medications.
Between January and October 2019, 131,000 new HIV infections
were reported in China, with sexual transmission the primary mode
of infection, Gilead said, citing data from the China National
Health Commission.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
August 11, 2020 08:43 ET (12:43 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024